Muhammad A Abdul-Ghani (M Abdul-Ghani, Muhammad Abdul Ghani, Muhammad Abdul-Ghani)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 33

Top Venues

Diabetes, obesity & metabolism

Diabetes care

Diabetes

The Journal of clinical endocrinology and metabolism

University of Texas Health Science Center at San Antonio

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Texas Health Science Center at San Antonio Dec 09 2004

United States

Associate Professor :: Medicine/Diabetes

Publications

Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke, Olga Larvenenko, Ralph A De Fronzo, Muhammad A Abdul-Ghani
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes care 47 (4) (2024)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke, Olga Larvenenko, Ralph A De Fronzo, Muhammad A Abdul-Ghani
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes care (2024)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke, Olga Larvenenko, Ralph A De Fronzo, Muhammad A Abdul-Ghani
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes care 47 (4) (2024)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke, Olga Larvenenko, Ralph A De Fronzo, Muhammad A Abdul-Ghani
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes care 47 (4) (2024)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Marissa Brown, Geoff Clarke, Olga Larvenenko, Ralph A De Fronzo, Muhammad A Abdul-Ghani
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. Diabetes care 47 (4) (2024)
Afif Nakhleh, Muhammad A Abdul-Ghani, Sivan Gazit, Adi Gross, Idit Livnat, Maya Greenbloom, Adva Yarden, Khaled Khazim, Naim Shehadeh, Cheli Melzer Cohen
Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Diabetes, obesity & metabolism 26 (8) (2024)
Afif Nakhleh, Muhammad A Abdul-Ghani, Sivan Gazit, Adi Gross, Idit Livnat, Maya Greenbloom, Adva Yarden, Khaled Khazim, Naim Shehadeh, Cheli Melzer Cohen
Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria. Diabetes, obesity & metabolism (2024)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism (2023)
Muhammad A Abdul-Ghani, Ralph A DeFronzo
Fasting Hyperinsulinemia and Obesity: Cause or Effect. The Journal of clinical endocrinology and metabolism (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
Siham Abdelgani, Ahmed Khattab, John Adams, Gozde Baskoy, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
The impact of increased hepatic glucose production caused by empagliflozin on plasma glucose concentration in individuals with type 2 diabetes and nondiabetic individuals. Diabetes, obesity & metabolism 26 (3) (2023)
Siham Abdelgani, Ahmad Khatab, John Adams, Mohamed Abu-Farha, Guisepe Daniele, Fahd Al-Mulla, Stefano Del Prato, Ralph A DeFronzo, Muhammad A Abdul-Ghani
Distinct Mechanisms Responsible for the Increase in Glucose Production and Ketone Formation Caused by Empagliflozin in T2DM Patients. Diabetes care (2023)
J David Spence, Catherine Viscoli, Walter N Kernan, Lawrence H Young, Karen Furie, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani, Paresh Dandona, Catherine M Viscoli
Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. Diabetes, obesity & metabolism 24 (6) (2022)
Tamam Abdul-Ghani, Curtiss Puckett, Osama Migahid, Siham Abdelgani, Ayman Migahed, John Adams, Curtis Triplitt, Muhammad Abdul-Ghani, Amin Jayyousi, Muhammad A Abdul-Ghani
Type 2 diabetes subgroups and response to glucose-lowering therapy: Results from the EDICT and Qatar studies. Diabetes, obesity & metabolism 24 (9) (2022)
Olga Lavynenko, Muhammad A Abdul-Ghani, Mariam Alatrach, Curtiss Puckett, John Adams, Siham Abdelgani, Naim Alkhouri, Curtis Triplitt, Geoffrey D Clarke, Juan A Vasquez, Jinqi Li, Eugenio Cersosimo, Francesco Rubino, Muhammad Abdul-Ghani
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). Diabetes, obesity & metabolism 24 (5) (2022)
Alexander J Moody, Marjorie Molina-Wilkins, Geoffrey D Clarke, Aurora Merovci, Carolina Solis-Herrera, Eugenio Cersosimo, Robert J Chilton, Patricia Iozzo, Francesco Rubino, Muhammad A Abdul-Ghani, Muhammad Abdul-Ghani
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes, obesity & metabolism (2022)
Jiyoon Ryu, Jason T Hadley, Zhi Li, Feng Dong, Huan Xu, Xiaoban Xin, Ye Zhang, Cang Chen, Senlin Li, Xiaoning Guo, Jared L Zhao, Robin J Leach, Muhammad A Abdul-Ghani, Ralph A De Fronzo, Amrita Kamat, Feng Liu, Lily Q Dong
Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration. Diabetes 70 (6) (2021)
S Abdelgani, C Puckett, J Adams, C Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes. The Journal of clinical endocrinology and metabolism 106 (12) (2021)
Ralph A De Fronzo, Muhammad A Abdul-Ghani
Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. Diabetes spectrum : a publication of the American Diabetes Association 34 (3) (2021)
Vasudha Ahuja, Pasi Aronen, T A Pramodkumar, Helen Looker, Angela Chetrit, Aini H Bloigu, Auni Juutilainen, Cristina Bianchi, Lucia La Sala, Ranjit Mohan Anjana, Rajendra Pradeepa, Ulagamadesan Venkatesan, Sarvanan Jebarani, Viswanathan Baskar, Teresa Vanessa Fiorentino, Patrick Timpel, Ralph A De Fronzo, Antonio Ceriello, Stephano Del Prato, Muhammad A Abdul-Ghani, Sirkka Keinänen-Kiukaanniemi, Rachel Dankner, Peter H Bennett, William C Knowler, Peter Schwarz, Giorgio Sesti, Rie Oka, Viswanathan Mohan, Leif Groop, Jaakko Tuomilehto, Samuli Ripatti, Michael Bergman, Tiinamaija Tuomi
Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. Diabetes care 44 (4) (2021)
Siham Abdelgani, Curtiss Puckett, John Adams, Curtis Triplitt, Muhammad Abdul-Ghani, Muhammad A Abdul-Ghani
Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study. Diabetes, obesity & metabolism 23 (7) (2021)
Muhammad A Abdul-Ghani, Osama Migahid, Ayman Megahed, Muhammad Abdul-Ghani, Ebaa Al-Ozairi, Amin Jayyousi
Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study. Diabetes, obesity & metabolism 22 (12) (2020)
Aurora Merovci, Devjit Tripathy, Xi Chen, Ivan Valdez, Muhammad A Abdul-Ghani, Carolina Solis-Herrera, Francesco Rubino, Ralph A De Fronzo
Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. Diabetes 70 (1) (2020)
Muhammad A Abdul-Ghani, Curtiss Puckett, John Adams, Ahmad Khattab, Gozde Baskoy, Eugenio Cersosimo, Curtis Triplitt, Ralph A De Fronzo
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Diabetes care 44 (2) (2020)
Francesco Rubino, Muhammad A Abdul-Ghani, Ralph A De Fronzo
Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance. Diabetes 70 (2) (2020)
Saadallah Iskandar, Ayman Migahid, Dalia Kamal, Osama Megahed, Ralph A DeFronzo, Mahmoud Zirie, Amin Jayyousi, Mahmood Al Jaidah, Muhammad A Abdul-Ghani
Glycated hemoglobin versus oral glucose tolerance test in the identification of subjects with prediabetes in Qatari population. BMC endocrine disorders 19 (1) (2019)
Paola Binda, Roy Eldor, Claudia Huerta, John Adams, John Lancaster, Peter Fox, Stefano Del Prato, Ralph DeFronzo, Muhammad A Abdul-Ghani, Giuseppe Daniele
Exenatide modulates visual cortex responses. Diabetes/metabolism research and reviews 35 (6) (2019)
Muhammad A Abdul-Ghani, Osama Migahid, Ayman Megahed, Rajvir Singh, Dalia Kamal, Ralph A DeFronzo, Amin Jayyousi
Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study. Diabetes, obesity & metabolism 20 (4) (2018)
Geoffrey D Clarke, Marjorie Molina-Wilkins, Carolina Solis-Herrera, Verna Mendez, Adriana Monroy, Eugenio Cersosimo, Robert J Chilton, Muhammad A Abdul-Ghani, Muhammad Abdul-Ghani
Impaired left ventricular diastolic function in T2DM patients is closely related to glycemic control. Endocrinology, diabetes & metabolism 1 (2) (2018)
Muhammad A Abdul-Ghani, Osama Migahid, Ayman Megahed, Rajvir Singh, Mohammad Fawaz, Muhammad Abdul-Ghani, Amin Jayyousi
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study. Diabetes, obesity & metabolism 21 (3) (2018)
Hussein Al Jobori, Giuseppe Daniele, John Adams, Eugenio Cersosimo, Curtis Triplitt, Ralph A DeFronzo, Muhammad A Abdul-Ghani
Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes, obesity & metabolism 19 (6) (2017)
Luke Norton, Christopher E Shannon, Marcel Fourcaudot, Cheng Hu, Niansong Wang, Wei Ren, Jun Song, Muhammad A Abdul-Ghani, Ralph A DeFronzo, Jimmy Ren, Weiping Jia
Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes, obesity & metabolism 19 (9) (2017)

Muhammad A Abdul-Ghani.css-eqlu8i{font-size:small;padding-left:4px;} (M Abdul-Ghani, Muhammad Abdul Ghani, Muhammad Abdul-Ghani)

Publication Activity (10 Years)

Top Topics

Top Venues

Muhammad A Abdul-Ghani (M Abdul-Ghani, Muhammad Abdul Ghani, Muhammad Abdul-Ghani)